Cargando…
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2. Lenvat...
Autores principales: | Kobayashi, Satoshi, Fukushima, Taito, Ueno, Makoto, Moriya, Satoshi, Chuma, Makoto, Numata, Kazushi, Tsuruya, Kota, Hirose, Shunji, Kagawa, Tatehiro, Hattori, Nobuhiro, Watanabe, Tsunamasa, Matsunaga, Kotaro, Suzuki, Michihiro, Uojima, Haruki, Hidaka, Hisashi, Kusano, Chika, Suzuki, Motoko, Morimoto, Manabu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080183/ https://www.ncbi.nlm.nih.gov/pubmed/35525913 http://dx.doi.org/10.1186/s12885-022-09625-x |
Ejemplares similares
-
Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021) -
Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023) -
Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020) -
The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
por: Kawamura, Atsushi, et al.
Publicado: (2022) -
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
por: Komiyama, Satoshi, et al.
Publicado: (2020)